ASCO 2019

CytImmune is excited to announce that our collaborative work with the US National Cancer Institute has resulted in an ASCO abstract. ASCO Submission Category Developmental Therapeutics and Tumor Biology (Nonimmuno), New Targets and New Technologies Authors and Institutions Naris Nilubol, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, MD 208921 David Oarr and Lawrence Tamarkin, …

The Tumor Micro Environment is Under a lot of Pressure

      The tumor micro-environment is a hot topic these days. I suspect it has a lot to do with the rise of immunotherapy and the delta in performance of CAR-T therapies between hematological cancers versus solid tumors, which represent the majority of cancers. This year’s AACR meeting is producing more than a few…

Has nanotechnology failed cancer patients?

Negative news abounded for cancer based nanotechnologies in 2016. From the outside, it might appear that its promise has faded. The reality is far from the truth. Like many great endeavors, past failures are shining a bright light on the path forward.